Serum interleukin-6 in seropositive rheumatoid arthritis and response to tocilizumab: An observational study

OBJECTIVE: There is no clinically useful biomarker as a predictor of response to any class of biological disease-modifying antirheumatic drugs (bDMARD). Serum interleukin-6 (IL-6) has a major role in the pathogenesis of rheumatoid arthritis (RA) and its serum level in patients of RA may predict resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Abhishek, Bhakuni, D. S., Kartik, Sivasami, Hegde, Arun, Shanmuganandan, K., Singh, Kavita, Vasdev, Vivek, MN, Arjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medical Research and Education Association 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10089141/
https://www.ncbi.nlm.nih.gov/pubmed/35110134
http://dx.doi.org/10.5152/eurjrheum.2021.20202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10089141/
https://www.ncbi.nlm.nih.gov/pubmed/35110134
http://dx.doi.org/10.5152/eurjrheum.2021.20202

Ejemplares similares